Javascript must be enabled to continue!
EXTH-119. Targeting myddosome signaling to improve immunotherapy in melanoma brain metastases
View through CrossRef
Abstract
BACKGROUND
Melanoma brain metastases (MBM) develop in up to 60% of patients with metastatic melanoma (MM) and are a major driver of mortality. First-line treatment typically includes immune checkpoint blockade (ICB) with anti-PD-1 and anti-CTLA-4, often combined with surgical resection or stereotactic radiosurgery. However, the brain remains a frequent site of treatment resistance, due to limited blood-brain barrier (BBB) penetrance of therapeutics, poor tumor lymphocyte (TIL) infiltration, and the presence of immunosuppressive tumor-associated myeloid cells (TAMs). We recently identified increased activation of the myddosome signaling pathway in TAMs within MBM, suggesting a mechanistic basis for their suppressive phenotype. IRAK-4, a critical downstream effector of MyD88, represents a potential target for TAM reprogramming. We have shown that the IRAK-4 inhibitor emavusertib (CA-4948), an oral small molecule, crosses the BBB and achieves therapeutic levels in the brain. We hypothesize that emavusertib can alleviate myeloid cell–mediated immune suppression, thereby enhancing the response to ICB in MBM.
METHODS
Single-cell RNA sequencing of MM and MBM patient samples was used to assess myddosome activation. Preclinical melanoma models (cutaneous and intracranial) were treated with emavusertib alone or in combination with anti-PD-1 ICB. Tumor burden and survival were assessed. Immune responses were evaluated using flow cytometry, immunohistochemistry, and cytokine profiling in tumor tissue and cerebrospinal fluid.
RESULTS
Myddosome signaling was elevated in TAMs from MM samples, including MBM. Emavusertib reduced myeloid-derived immunosuppressive cytokines and decreased recruitment of peripheral TAMs. Combination treatment with emavusertib and anti-PD-1 significantly reduced tumor growth and improved survival across three models. Increased lymphocyte infiltration and IFNγ expression indicated enhanced antitumor immunity.
CONCLUSION
Targeted IRAK-4 inhibition with emavusertib reprograms suppressive TAMs and enhances response to anti-PD-1 therapy in MBM models. These findings support emavusertib as a promising adjuvant to ICB in MM, providing the foundation for a first in human clinical trial (NCT05669352).
Oxford University Press (OUP)
Title: EXTH-119. Targeting myddosome signaling to improve immunotherapy in melanoma brain metastases
Description:
Abstract
BACKGROUND
Melanoma brain metastases (MBM) develop in up to 60% of patients with metastatic melanoma (MM) and are a major driver of mortality.
First-line treatment typically includes immune checkpoint blockade (ICB) with anti-PD-1 and anti-CTLA-4, often combined with surgical resection or stereotactic radiosurgery.
However, the brain remains a frequent site of treatment resistance, due to limited blood-brain barrier (BBB) penetrance of therapeutics, poor tumor lymphocyte (TIL) infiltration, and the presence of immunosuppressive tumor-associated myeloid cells (TAMs).
We recently identified increased activation of the myddosome signaling pathway in TAMs within MBM, suggesting a mechanistic basis for their suppressive phenotype.
IRAK-4, a critical downstream effector of MyD88, represents a potential target for TAM reprogramming.
We have shown that the IRAK-4 inhibitor emavusertib (CA-4948), an oral small molecule, crosses the BBB and achieves therapeutic levels in the brain.
We hypothesize that emavusertib can alleviate myeloid cell–mediated immune suppression, thereby enhancing the response to ICB in MBM.
METHODS
Single-cell RNA sequencing of MM and MBM patient samples was used to assess myddosome activation.
Preclinical melanoma models (cutaneous and intracranial) were treated with emavusertib alone or in combination with anti-PD-1 ICB.
Tumor burden and survival were assessed.
Immune responses were evaluated using flow cytometry, immunohistochemistry, and cytokine profiling in tumor tissue and cerebrospinal fluid.
RESULTS
Myddosome signaling was elevated in TAMs from MM samples, including MBM.
Emavusertib reduced myeloid-derived immunosuppressive cytokines and decreased recruitment of peripheral TAMs.
Combination treatment with emavusertib and anti-PD-1 significantly reduced tumor growth and improved survival across three models.
Increased lymphocyte infiltration and IFNγ expression indicated enhanced antitumor immunity.
CONCLUSION
Targeted IRAK-4 inhibition with emavusertib reprograms suppressive TAMs and enhances response to anti-PD-1 therapy in MBM models.
These findings support emavusertib as a promising adjuvant to ICB in MM, providing the foundation for a first in human clinical trial (NCT05669352).
Related Results
Brain Organoids, the Path Forward?
Brain Organoids, the Path Forward?
Photo by Maxim Berg on Unsplash
INTRODUCTION
The brain is one of the most foundational parts of being human, and we are still learning about what makes humans unique. Advancements ...
Abstract LB203: Targeted inhibition of IRAK-4 with CA-4948 (emavusertib) sensitizes metastatic brain melanoma to anti-PD-1 immune checkpoint blockade
Abstract LB203: Targeted inhibition of IRAK-4 with CA-4948 (emavusertib) sensitizes metastatic brain melanoma to anti-PD-1 immune checkpoint blockade
Abstract
Introduction: The unique microenvironment within the brain alongside restrictions imparted by the blood brain barrier (BBB) create a sanctuary site for tumo...
The use of resiquimod (RSQ) in treatment of melanoma
The use of resiquimod (RSQ) in treatment of melanoma
Melanoma is responsible for most skin cancer-related deaths, despite accounting for only 1% of all skin cancer cases. At present, surgery is considered the most promising treatment...
Prognostic factors for survival in melanoma patients with brain metastases
Prognostic factors for survival in melanoma patients with brain metastases
AbstractBACKGROUND:One of the most common and deadly complications of melanoma is brain metastases. The outcomes of advanced melanoma patients who developed brain metastases were r...
Abstract 2902: CA-4948 (emavusertib) improves treatment response of preclinical metastatic brain melanoma to anti-PD-1 immune checkpoint blockade
Abstract 2902: CA-4948 (emavusertib) improves treatment response of preclinical metastatic brain melanoma to anti-PD-1 immune checkpoint blockade
Abstract
Background: Although recent advances in immunotherapy for metastatic melanoma have transformed the treatment paradigm for a disease that once carried a grim...
[RETRACTED] Gro-X Brain Reviews - Is Gro-X Brain A Scam? v1
[RETRACTED] Gro-X Brain Reviews - Is Gro-X Brain A Scam? v1
[RETRACTED]➢Item Name - Gro-X Brain➢ Creation - Natural Organic Compound➢ Incidental Effects - NA➢ Accessibility - Online➢ Rating - ⭐⭐⭐⭐⭐➢ Click Here To Visit - Official Website - ...
Abstract LB163: Germline pathogenic variants in melanoma patients
Abstract LB163: Germline pathogenic variants in melanoma patients
Abstract
Background: The etiology of melanoma has generally been thought to be exposure to UV radiation (sun and sun tanning lamps). However, the percent of melanoma...
The Risk of Subsequent Invasive Melanoma after a Primary in Situ or Invasive Melanoma in a High Incidence Country (New Zealand)
The Risk of Subsequent Invasive Melanoma after a Primary in Situ or Invasive Melanoma in a High Incidence Country (New Zealand)
Abstract
Background
Patients with invasive melanoma are at increased risk of developing subsequent invasive melanoma, but the ri...

